Company news
Celldex Therapeutics, Inc. news in 2023
Celldex Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
November 26, 2023
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
November 6, 2023
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
November 5, 2023
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
November 4, 2023
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 1, 2023
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
September 25, 2023
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
September 24, 2023
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 7, 2023
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
July 10, 2023
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
July 5, 2023
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
June 9, 2023
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
June 7, 2023
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
May 30, 2023
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
May 14, 2023
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 3, 2023
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 28, 2023
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
February 27, 2023
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
February 25, 2023
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
February 15, 2023
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
February 14, 2023
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023
February 2, 2023